The central role of dysregulated kinase activity in the etiology of progressive disorders,
including cancer, has fostered incremental efforts on drug discovery programs over the past …

Autoimmune hemolytic anemias (AIHAs) are rare and heterogeneous disorders
characterized by the destruction of red blood cells through warm or cold antibodies. There is …

Because mutations, overexpression, and dysregulation of protein kinases play essential
roles in the pathogenesis of many illnesses, this enzyme family has become one of the most …

Background: Despite an increase in the number of therapies available to treat patients with
immune thrombocytopenia (ITP), there are minimal data from randomized trials to assist …

Over the last decade, there have been numerous developments and changes in treatment
practices for the management of patients with immune thrombocytopenia (ITP). This article is …

Key Clinical Points Immune Thrombocytopenia Immune thrombocytopenia (ITP) is
diagnosed in patients with a platelet count below 100,000 per cubic millimeter in whom …

The two thrombopoietin receptor agonists (TPO-RA), eltrombopag and romiplostim, were
licensed in the US for treatment of immune thrombocytopenia (ITP) in 2008 and, since then …

Primary immune thrombocytopenia is an autoimmune disease associated with a reduced
peripheral blood platelet count. The phenotype is variable with some patients suffering no …

Primary immune thrombocytopenia (ITP) is an immune-mediated bleeding disorder
characterized by decreased platelet counts and an increased risk of bleeding. Multiple …

Immune thrombocytopenia (ITP) is the most common acquired thrombocytopenia after
chemotherapy-induced thrombocytopenia. Existing guidelines describe the management …